- Open
- 26.50
- High
- 27.85
- Low
- 26.60
- Close
- 27.85
- Change
- +0.50 (1.89%)
- Volume
- 450,524
| 30 Jun 2026 | 07:00:04 | Interim Results |
| 2 Jun 2026 | 07:00:05 | Holding(s) in Company |
| 22 May 2026 | 07:00:01 | Trading update for the 6-months ended 31/03/2026 |
| 12 May 2026 | 07:00:08 | Spinout and Completion of Financing of RSH |
| 24 Feb 2026 | Annual Report and Accounts (to 2025-09-30) | |
| 23 Oct 2024 | Annual Report and Accounts (to 2024-03-31) | |
| 4 Aug 2023 | Annual Report and Accounts (to 2023-03-31) |
RUA Life Sciences PLC is a company focused on the development and manufacturing of medical devices, particularly in the cardiovascular sector. It leverages its intellectual property and expertise in polymer technology to provide contract manufacturing services and develop proprietary medical devices. The company operates primarily in the healthcare market, serving clients involved in medical device innovation and production.
| 30 Jun 2026 | 07:00:04 | Interim Results |
| 2 Jun 2026 | 07:00:05 | Holding(s) in Company |
| 22 May 2026 | 07:00:01 | Trading update for the 6-months ended 31/03/2026 |
| 12 May 2026 | 07:00:08 | Spinout and Completion of Financing of RSH |
| 24 Feb 2026 | Annual Report and Accounts (to 2025-09-30) | |
| 23 Oct 2024 | Annual Report and Accounts (to 2024-03-31) | |
| 4 Aug 2023 | Annual Report and Accounts (to 2023-03-31) |
RUA Life Sciences PLC is a company focused on the development and manufacturing of medical devices, particularly in the cardiovascular sector. It leverages its intellectual property and expertise in polymer technology to provide contract manufacturing services and develop proprietary medical devices. The company operates primarily in the healthcare market, serving clients involved in medical device innovation and production.
| 17 Mar 2026 |
| 16:54:10 |
| Result of AGM |
| 22 May 2026 |
| RUA Life Sciences expects improved EBITDA as revenues rise |
| 12 May 2026 | AIM movers: Frontier Developments upgraded and RUA Life Sciences spinning off heart valve business |
| 4 Nov 2025 | AIM movers: Kore Potash formal sale process and URU Metals fundraising for Zeb nickel project |
| 17 Mar 2026 |
| 16:54:10 |
| Result of AGM |
| 22 May 2026 |
| RUA Life Sciences expects improved EBITDA as revenues rise |
| 12 May 2026 | AIM movers: Frontier Developments upgraded and RUA Life Sciences spinning off heart valve business |
| 4 Nov 2025 | AIM movers: Kore Potash formal sale process and URU Metals fundraising for Zeb nickel project |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £624m | +0.3% | |
| £186m | +0.1% | |
| £80m | +0.2% | |
RUARUA Life Sciences PLC | £17m | +1.4% |
| £4m | -0.3% | |
| £4m | -0.4% |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £624m | +0.3% | |
| £186m | +0.1% | |
| £80m | +0.2% | |
RUARUA Life Sciences PLC | £17m | +1.4% |
| £4m | -0.3% | |
| £4m | -0.4% |
